BioElectronics + Medtronic Synergy - Unlocking Non-Invasive Vagus Nerve Therapy:
Medtronic’s Vagus Nerve Expertise:
Neurological disorders (e.g. epilepsy)
Psychiatric conditions (e.g. depression)
Autoimmune diseases (e.g. Crohn’s, RA)
ActiPatch: A Breakthrough Path to Transcutaneous VNS
ActiPatch®, developed by BioElectronics Corp., is a non-invasive pulsed shortwave therapy device originally used for pain and inflammation management. Its potential to target the vagus nerve non-surgically represents a disruptive innovation in neuromodulation.
Why It Works:
The cervical branch of the vagus nerve is anatomically close to the surface of the neck, allowing transcutaneous access.
ActiPatch emits low-frequency electromagnetic fields, which could be adapted to influence vagus signaling.
Studies suggest similar waveforms may alter autonomic tone, inflammation, and pain sensitivity—hallmarks of effective vagus nerve stimulation.
With design enhancements for neural targeting, ActiPatch could become the first over-the-counter wearable VNS platform, supporting chronic care from home.
Strategic Implication: Medtronic + BioElectronics Corp.
The potential collaboration between Medtronic and BioElectronics Corp. opens the door to:
Precision-guided tVNS using Medtronic’s monitoring sensors
AI-powered stimulation algorithms informed by EMG data
Affordable neuromodulation wearables for mass adoption
This fusion could redefine digital therapeutics and bioelectronic medicine, with ActiPatch leading the charge in accessible vagus nerve therapy.
Medtronic’s Vagus Nerve Expertise:
Neurological disorders (e.g. epilepsy)
Psychiatric conditions (e.g. depression)
Autoimmune diseases (e.g. Crohn’s, RA)
ActiPatch: A Breakthrough Path to Transcutaneous VNS
ActiPatch®, developed by BioElectronics Corp., is a non-invasive pulsed shortwave therapy device originally used for pain and inflammation management. Its potential to target the vagus nerve non-surgically represents a disruptive innovation in neuromodulation.
Why It Works:
The cervical branch of the vagus nerve is anatomically close to the surface of the neck, allowing transcutaneous access.
ActiPatch emits low-frequency electromagnetic fields, which could be adapted to influence vagus signaling.
Studies suggest similar waveforms may alter autonomic tone, inflammation, and pain sensitivity—hallmarks of effective vagus nerve stimulation.
With design enhancements for neural targeting, ActiPatch could become the first over-the-counter wearable VNS platform, supporting chronic care from home.
Strategic Implication: Medtronic + BioElectronics Corp.
The potential collaboration between Medtronic and BioElectronics Corp. opens the door to:
Precision-guided tVNS using Medtronic’s monitoring sensors
AI-powered stimulation algorithms informed by EMG data
Affordable neuromodulation wearables for mass adoption
This fusion could redefine digital therapeutics and bioelectronic medicine, with ActiPatch leading the charge in accessible vagus nerve therapy.
1
